Success Metrics

Clinical Success Rate
79.6%

Based on 78 completed trials

Completion Rate
80%(78/98)
Active Trials
4(3%)
Results Posted
31%(24 trials)
Terminated
20(17%)

Phase Distribution

Ph phase_2
30
26%
Ph not_applicable
6
5%
Ph early_phase_1
1
1%
Ph phase_1
21
18%

Phase Distribution

22

Early Stage

30

Mid Stage

0

Late Stage

Phase Distribution58 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
21(36.2%)
Phase 2Efficacy & side effects
30(51.7%)
N/ANon-phased studies
6(10.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

76.5%

78 of 102 finished

Non-Completion Rate

23.5%

24 ended early

Currently Active

4

trials recruiting

Total Trials

117

all time

Status Distribution
Active(5)
Completed(78)
Terminated(24)
Other(10)

Detailed Status

Completed78
Terminated20
unknown10
Withdrawn4
Active, not recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
117
Active
4
Success Rate
79.6%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (1.7%)
Phase 121 (36.2%)
Phase 230 (51.7%)
N/A6 (10.3%)

Trials by Status

withdrawn43%
recruiting11%
active_not_recruiting33%
terminated2017%
completed7867%
unknown109%
not_yet_recruiting11%

Recent Activity

Clinical Trials (117)

Showing 20 of 117 trialsScroll for more
NCT01199562

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Active Not Recruiting
NCT01196936Phase 2

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Active Not Recruiting
NCT00897117

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

Recruiting
NCT00812669Phase 2

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Completed
NCT00436254Phase 1

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Completed
NCT00544414Phase 2

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Completed
NCT00410956Phase 2

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Completed
NCT00499083Phase 2

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Completed
NCT00665457Phase 2

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Terminated
NCT00898456

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

Active Not Recruiting
NCT00372736Phase 1

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Completed
NCT04445532

Hepatobiliary Tumors Tissue Samples Acquisition

Unknown
NCT00900055

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Completed
NCT03127111

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Not Yet Recruiting
NCT01253668Phase 2

Brivanib Metastatic Renal Cell Carcinoma

Terminated
NCT01280643Not Applicable

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Terminated
NCT00955435

Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15

Unknown
NCT00601289Phase 2

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Withdrawn
NCT00589056Phase 1

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Completed
NCT00896727

S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

Completed

Drug Details

Intervention Type
GENETIC
Total Trials
117